营收数据 - 2024年第三季度总营收为8500万美元，2023年同期为1.87亿美元[12] - 2024年前九个月总营收为59385.1万美元2023年同期为69236.3万美元[28] - 2024年第三季度产品销售额为3821万美元2023年同期为2231万美元[28] 费用支出 - 2024年第三季度研发费用为8700万美元，2023年同期为1.06亿美元[14] - 2024年第三季度销售总务管理支出为7100万美元，2023年同期为1.07亿美元[14] - 2024年第三季度研发和销售总务管理支出较2023年同期减少约26%[7] - 目标2025年全年研发和销售总务管理支出合计约5亿美元，2026年约3.5亿美元[8] 盈利亏损情况 - 2024年第三季度净亏损1.21亿美元，2023年同期净亏损1.31亿美元[15] - 2024年第三季度净亏损为12130万美元[28] - 2024年前九个月基本和稀释后每股净亏损为0.71美元2023年同期为3.94美元[28] - 2024年第三季度基本和稀释后每股净亏损为0.76美元2023年同期为1.26美元[28] 现金及相关财务数据 - 截至2024年9月30日现金等为9.24亿美元，2023年12月31日为5.84亿美元[15] - 2024年9月30日现金及现金等价物为57363万美元2023年12月为56850.5万美元[29] - 2024年9月30日可转换应付票据为16926.5万美元[29] - 2024年9月30日股东总赤字为52643.6万美元[29] 业务指引 - 2024年全年产品销售指引反映2024年上半年约1亿美元的预购协议剂量交付和2024年下半年7500万至1.25亿美元的商业市场销售[17] - 2024年全年许可版税和其他收入指引包括从赛诺菲协议5亿美元预付款中确认的4.5亿美元收入以及来自合作伙伴相关活动的2500万美元版税和其他收入[17] 临床试验相关 - 美国食品药品监督管理局解除对新冠 - 流感组合和独立流感疫苗候选药物的临床试验搁置[4] 股份相关数据 - 2024年第三季度加权平均普通股数为160049股2023年同期为103429股[28] - 2024年前九个月加权平均普通股数为149486股2023年同期为93046股[28]

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total revenue of $85 million in the third quarter of 2024 Ended the third quarter of 2024 with $1 billion in cash and receivables Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and older Outlined R&D strategy based on its proven technology platform Updates full year ...

Key TakeawaysNovavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.Regulators stopped testing last month as one patient had a serious adverse event after taking the shot.The company said further information supported its contention that the vaccine did not cause the problem, and it will now move to resume its research as soon as possible. Novavax (NVAX) shares edged higher Monday after the drugmaker announ ...

Novavax (NVAX) is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported quarter, the company’s earnings missed estimates by 45.60%.The Zacks Consensus Estimate for sales is pegged at $57.3 million while that for earnings is pinned at a loss of 87 cents per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Factors Shaping NVAX’s Upcoming ResultsAlthough Novavax secured the FDA’s authorization for an updated version of its protei ...

GAITHERSBURG, Md., Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase 3 trial following the determination that No ...

The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 12, 2024, might help the stock move higher if these key numbers are ...

GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows: Conference call details: Date: November 12, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3Y6irHG Dia ...

Novavax (NVAX) closed the latest trading day at $10.07, indicating a -1.76% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day. At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq gained 0.78%. Shares of the vaccine maker have depreciated by 18.84% over the course of the past month, underperforming the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67%. Investors will be eagerly watching for the performance of Nov ...

文章核心观点 1. 投资者应该警惕三种可能预示着医疗保健股票即将下跌的迹象 [1] 2. 这些迹象包括: - 在一段高利润或事件驱动的增长期后进行投资 [2][3][4] - 管理层的时间表一再被推迟 [5][6][7] - 公司频繁进入最新最热门的领域 [8][9][10] 根据相关目录分别进行总结 1. 在一段高利润或事件驱动的增长期后进行投资 - 繁荣时期不会一直持续 [2] - 当推动繁荣的趋势开始消退时,市场往往会抛售之前的赢家股票 [2] - 以Teladoc和辉瑞为例,它们在疫情期间获得了大量需求,收入大幅增长,但随后市场饱和,增长难以持续 [2][3][4] - 投资者应关注公司的长期前景,而不是短期业绩驱动因素 [4] 2. 管理层的时间表一再被推迟 - 在医疗行业,由于需要与政府机构、保险公司和医院等缓慢运转的实体打交道,延迟是常见和不可避免的 [5] - 但如果时间表一再被推迟,即使管理层保证情况正在好转,这可能是股票价值面临高风险的信号 [5][6][7] - 以Novavax疫苗推出延迟为例,反复的推迟损害了投资者的信任 [6][7] 3. 公司频繁进入最新最热门的领域 - 公司进入新的热门领域是正常的,但如果一家生物制药公司频繁推出新的管线项目,追随每个新的药物开发趋势,股价可能会下跌 [8][9][10] - 因为在公司的核心领域进行研发活动,成功开发新药的可能性最高 [8][9][10] - 如果一家专注于干性皮肤的公司突然宣布进入完全不相关的领域,如过度日间嗜睡,股东可能会遭受损失 [10] - 药物开发已经很具挑战性,如果公司进一步复杂化任务,将其扩展到明显超出核心能力的领域,风险会更高 [10]

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or “the Company”) (NASDAQ: NVAX). Investors who purchased Novavax securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/NVAX. Investigation Details On October 16, 2024, Novavax issued a press release “announc[ing] that the U.S. Food and Drug Adminis ...